REQUEST FOR PROPOSAL: PROGRAM TO ACCELERATE CLINICAL TRIALS (PACT)

Funding Agency:
Alzheimer’s Drug Discovery Foundation

The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered.

This funding opportunity prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP.

Deadlines for Letters of Intent: Feb. 5, 2021; May 28, 2021; Oct. 1, 2021

Agency Website

Eligibility Requirements

Funding is open to researchers and clinicians worldwide at:

  • Academic medical centers and universities or nonprofits. Industry partnerships are strongly encouraged.
  • Biotechnology companies. Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones. Existing companies and new startups are both eligible.

Amount

$5,000,000

Amount Description

Up to $5 million based on stage and scope of research. Depending on the availability of funds, in certain cases, well-justified larger budgets may be considered. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.

Funding Type

Grant

Eligibility

Faculty
Medical Fellow/Resident
Post Doctoral Fellows

Category

Engineering and Physical Sciences
Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

May 28, 2021